

# Neurotech

22 December 2020

## Results of General Meeting

**Neurotech International Limited (ASX:NTI)** ('NTI' or 'the Company') today held a General Meeting of Members at Suite 41, 145 Stirling Highway, Nedlands WA 6009.

All resolutions were determined by a poll.

The outcome of each resolution put to shareholders at the General Meeting is set out in the Annexure which accompanies this release.

### Authority

This announcement has been authorised for release by Winton Willesee, Director.

### Further Information

Erlyn Dale  
Company Secretary  
erlyn@azc.com.au  
+61 424 676 671

Winton Willesee  
Non-Executive Director  
winton@azc.com.au  
+61 410 667 844

### About Neurotech

Neurotech International Limited is a medicinal cannabis company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary DOLCE/NTI cannabis strains which include CBDA, CBDP and CBDB. The licensed strains contain < 0.3% THC providing a clearer pathway to regulatory approval as compared to all other cannabis companies that contain far higher levels of THC. Neurotech is also commercialising *Mente*, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and *Mente* Autism please visit:

<http://www.neurotechinternational.com>

<http://www.mentetech.com>

---

#### Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway  
Nedlands, Western Australia 6009

[www.neurotechinternational.com](http://www.neurotechinternational.com)

# Disclosure of Proxy Votes

## NEUROTECH INTERNATIONAL LIMITED

General Meeting

Tuesday, 22 December 2020



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Ratification of issue of Tranche 1 Placement Shares to Placement Participants	P	39,397,048	38,771,543 98.41%	508,839 1.29%	0	116,666 0.30%	38,888,209 98.71%	508,839 1.29%	0
2 Approval to issue Tranche 2 Placement Shares to Placement Participants	P	40,803,048	40,177,543 98.47%	508,839 1.25%	0	116,666 0.29%	40,294,209 98.75%	508,839 1.25%	0
3 Approval for Director to participate in the Placement	P	40,803,048	40,177,543 98.47%	508,839 1.25%	0	116,666 0.29%	40,294,209 98.75%	508,839 1.25%	0
4 Approval to issue Options to Max Capital Pty Ltd	P	18,573,048	17,947,543 96.63%	508,839 2.74%	22,230,000	116,666 0.63%	18,064,209 97.26%	508,839 2.74%	22,230,000

